TruScreen Group (TRU) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with a welcome to shareholders, both in-person and online, and introduction of the board and executive team.

• Apologies noted for absent director; voting procedures and agenda outlined, including CEO presentation, formal resolutions, and general business.

• Introduced TruScreen's AI-enabled cervical cancer screening device and outlined the meeting agenda, including technology overview, market landscape, sales strategy, and financial performance.

• Voting conducted by poll, with results declared and lodged on NZX post-meeting.

Board and executive committee updates

• Board refreshed with new directors; Christine Pears replaced Juliet Hull, and Chris Horn retired after 13 years.

• Reece O'Connell appointed as a new director, bringing commercial and biotech expertise.

• Board composition adjusted for diversity and expertise, with focus on governance and audit.

• Tony Ho (Non-Executive Chairman) and Marty Dillon (CEO) provided contact details and led the meeting.

Financial performance review

• FY 2026 annual sales exceeded NZD 2.4 million, a 42% year-on-year growth.

• Total revenue for FY26 was NZ$2.8m, up 33% year-on-year.

• Market cap at NZD 15.7 million as of August 2026; 1,047,718,877 shares on issue.

• Net assets doubled due to fundraising and inventory investment, increasing 160% year-on-year.

• NZ$5m capital was raised in June 2026 through oversubscribed placements and rights offers.

• Accumulated losses at NZD 39.7 million; EBITDA remained unchanged at -NZ$2.2m.